Browse by author
Lookup NU author(s): Dr Yvette DrewORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The discovery that PARP inhibitors block an essential pathway of DNA repair in cells harbouring a BRCA mutation has opened up a new therapeutic avenue for high-grade ovarian cancers. BRCA1 and BRCA2 proteins are essential for high-fidelity repair of double-strand breaks of DNA through the homologous recombination repair (HRR) pathway. Deficiency in HRR (HRD) is a target for PARP inhibitors. The first PARP inhibitor, olaparib, has now been licensed for BRCA-mutated ovarian cancers. While mutated BRCA genes are individually most commonly associated with HRD other essential HRR proteins may be mutated or functionally deficient potentially widening the therapeutic opportunities for PARP inhibitors. HRD is the first phenotypically defined predictive marker for therapy with PARP inhibitors in ovarian cancer. Several different PARP inhibitors are being trialled in ovarian cancer and this class of drugs has been shown to be a new selective therapy for high-grade ovarian cancer. Around 20% of high-grade serous ovarian cancers harbour germline or somatic BRCA mutations and testing for BRCA mutations should be incorporated into routine clinical practice. The expanded use of PARP inhibitors in HRD deficient (non-BRCA mutant) tumours using a signature of HRD in clinical practice requires validation. (C) 2016 Elsevier Ltd. All rights reserved.
Author(s): Ledermann JA, Drew Y, Kristeleit RS
Publication type: Review
Publication status: Published
Journal: European Journal of Cancer
Print publication date: 01/06/2016
Online publication date: 09/04/2016
Acceptance date: 07/03/2016
ISSN (print): 0959-8049
ISSN (electronic): 1879-0852
Publisher: ELSEVIER SCI LTD